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CHOLESTEROL LEVELS IN PANIC DISORDER, GENERALIZED
ANXIETY DISORDER AND MAJOR DEPRESSION
ACIOLY L.T. LACERDA*, DORGIVAL CAETANO**, SHEILA C. CAETANO***
ABSTRACT - Serum plasma total cholesterol levels were measured in 85 male or female outpatients with panic
disorder (PD;  N=41), generalized anxiety disorder (GAD;  N=23) and major depression (MD;  N=21) according
to DSM-IV criteria.  All the patients had a mean cholesterol level within the normal range;   males (N=22) and
females (N=63) had approximately the same serum cholesterol levels (p > .05).  No significant differences in
cholesterol levels emerged between PD, GAD and MD patient groups.  Both female PD and female GAD subjects
had a mean cholesterol level similar to their male counterparts (p>.05).  It is concluded that both Hayward and
colleagues and Bajwa et al. findings could not be replicated by our study.
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Níveis de colesterol no transtorno de pânico, transtorno de ansiedade generalizada e depressão maior
RESUMO - Foram medidos os níveis plasmáticos de colesterol total em 85 pacientes ambulatoriais com transtorno
de pânico (TP; N = 41), transtorno de ansiedade generalizada (TAG; N = 23) e depressão maior (DM; N = 21),
diagnosticados de acordo com os critérios do DSM-IV. O grupo de pacientes apresentou média do nível de
colesterol dentro da faixa normal; homens (N = 22) e mulheres (N = 63) tiveram aproximadamente os mesmos
níveis séricos de colesterol (p > 0,05). Não foram observadas diferenças nos níveis de colesterol entre os grupos
de pacientes com TP, TAG e DM. Mulheres com TP e as com TAG apresentaram média dos níveis de colesterol
semelhante aos seus pares masculinos (p > 0,05). Conclui-se que os resultados obtidos por Hayward et al. e por
Bajwa et al. não foram replicados neste estudo.
PALAVRAS-CHAVE: colesterol, transtorno de ansiedade generalizada, depressão maior, transtorno do
pânico.
In a study carried out by Coryell et al. 1,  male patients with panic disorder (PD) exhibited
excess mortality due to unnatural causes and to circulatory system disease as compared to age- and
gender-specific general population figures.  Similar results were reported in a 12-year follow-up of
115 outpatients with “anxiety neurosis”.  Again men had an excess in death which was attributed to
cardiovascular disease and suicide2.
Nesse et al3  found that patients with PD had an  increased adrenergic function (elevated
resting  heart rate, elevated levels of plasma epinephrine, cortisol and growth hormone, and mildly
elevated plasma norepinephrine levels) even in the absence of panic attacks.  Dimsdale and Herd4,
reviewed   60 studies relating plasma lipids and emotional arousal.  Most of these studies reported
that cholesterol increased from 8 to 65% above baseline under stressful conditions.  PD and anxious
patients, at least when they are ill, have lower threshold for stimuli (environmental, emotional, etc.).
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As a consequence, they feel under stress most of the time.  If stressful situations are related to higher
cholesterol levels, then one would expect for PD and generalized anxiety disorder (GAD) patients
higher plasma cholesterol levels than that found in the general population.
In Hayward et al. study 5, females (but not males) with panic disorder or agoraphobia had
significantly higher than expected cholesterol values that exceeded the 75th percentile of USA
references. Bajwa et al. 6 compared cholesterol levels of patients with PD, major depression (MD)
according to DSM-III-R, and normal controls matched for age and gender. They found that patients
with PD had significantly higher serum cholesterol levels than normal controls and those with MD.
Both studies hypothesized that higher cholesterol levels could be a result of noradrenergic activity,
placing these patients at greater risk for the development of cardiovascular disease.  That deserves
further study.  As in both studies PD was the only anxiety disorder included, it unclear whether these
findings are specific for PD or whether they related to any anxiety disorder.
To replicate and extend these findings, we measured  cholesterol levels in 3 groups of patients:
PD, GAD, and MD.
METHOD
Subjects were 85 male or female outpatients free of medication, enrolled in treatment in a university
hospital.  After clinical examination to rule out medical conditions, the patients were diagnosed as PD, GAD, and
MD, following DSM-IV criteria.  No instructions to change the patients’ usual dietary habits were given.  Blood
samples were drawn after a 12-hour fast and cholesterol serum levels were assessed by means of Chod-Top.
Comorbidity with alcohol/drug abuse  were excluded. Mean differences between two groups were tested by two-
tailed t-test, and for three groups by means of ANOVA.
RESULTS
Altogether the 3 groups (N = 85: PD+GAD+MD) had a mean (± SD) total cholesterol level
(mg/dl) of 178.3 ± 39.0 which lies within the normal range  (Table 1). Female patients (N = 63) had
a higher mean  (± SD) cholesterol level (182.4 ± 38.1) than males (N = 22; 170.6 ± 12.4), although
they weighted (61.8 ± 12.1) less than their male counterparts (65.4 ± 10.1).  These differences,
however,  did not reach significance (p > .05).
Table 2 shows that there were 41 individuals (33F and 8M) with PD, 23 (13F and 10M) with
GAD, and 21 (15F and 6M) with MD. The mean (± SD) cholesterol level (mg/dl) was highest for the
PD  patients  (182.4  ±  40.1), intermediate for GAD  (175.6 ± 31.3), and lowest for MD(173.6 ±
31.3), despite the fact that the latter were older. These differences, however, were not significant (F
= 0.46, df = 2; p = 0.6) and all the values lie within the normal range.
Table 1. Characteristics of the whole sample (panic disorder + generalized
anxiety disorder + major depression) in terms of gender, weight, and
cholesterol levels, and t-test on weight and cholesterol level by gender.
Gender Weight (Kg) Cholesterol levels (mg/dl)
Mean ± SD Mean ± SD
Female (N = 63) 61.8 ± 12.1 182.4 ± 38.1
Male (N = 22) 65.4 ± 10.1 170.6 ± 12.4
     P ns ns
Female + Male (N = 85) 62.7 ± 11.6 178.3 ± 39.0
ns, non-significant at 5%.
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Patients in each group were splitted by gender.  No significant difference in cholesterol levels
emerged between PD female patients (183.5 ± 35.3) when compared with male patients (180.4 ±
48.5) (p = 0.4), nor between GAD females (176.0 ± 32.1) and males (173.8 ± 31.8) (p = 0.4).
However, female patients with MD had a significantly higher mean (± SD) cholesterol level (186.3
± 40.4) than their male counterparts (141.8 ± 27.1) (p = 0.02).  ANOVA on age for the 3 groups
showed no statistically significant difference: GAD patients were the youngest with a mean age
(years) of 33.7 ± 8.6, followed by PD patients with a mean of 37.4 ± 12.9, and MD patients 40.8 ±
14.4 (F = 1.74; p = 0.2).
The 3 groups were pooled together and a regression analysis on cholesterol (dependent variable)
in relation to age was carried out. It yielded a highly significant coefficient (F = 7.7; p = 0.007)
which confirms findings widely reported in the literature of a strong correlation between age and
cholesterol levels.
DISCUSSION
Hayward et al.5 found that female PD subjects had a higher serum cholesterol level than
expected. Bajwa et al.6 reported that PD (male + female) individuals had a significantly higher
serum cholesterol level than normal controls or patients with MD.  These findings might suggest
that in PD subjects an increased noradrenergic activity would  lead to activation of the mechanism
of induction of lipoprotein lipase that results in an increase of free fatty acids in the serum.  High
cholesterol level plus increased noradrenergic function would place these individuals at higher  risk
to develop cardiovascular disease. That would be in line with Coryell and colleagues’ findings 1,2 of
excess mortality due to cardiovascular disease in males with panic or anxiety disorder.  Hence, the
treatment of panic or anxiety disorder would have a bearing on both increased noradrenergic activity
and cholesterol level, thus reducing the risk for cardiovascular disease.
This hypothesis, however, has been challenged by Feder7 who calls attention to the fact that
cholesterol levels are much strongly influenced by genetics and diet than by psychological stress.
Before one dwells on theories, the findings from which they were developed should be replicated
for the sake of consistency and validation.  Reifman and Windle8 could not replicate Hayward et al.5
and Bajwa et al. 6 studies in a male sample.  In this study the authors found approximately the same
cholesterol level values for panic disorder, major depression only, major depression with anxiety,
and normal controls (p > . 40).
Table 2. ANOVA on cholesterol levels and age between groups of patients with panic disorder (PD),
generalized anxiety disorder (GAD), major depression (MD), and t-test on cholesterol levels by sex.
Patients with Patients with Patients with Analysis
PD (N = 41) GAD (N = 23) MD (N = 21) F df p
Mean ± SD Mean ± SD Mean ± SD
Cholesterol levels (mg/dl) 182.4 ± 40.1 175.2 ± 31.3 173.6 ± 47.4 0.46 2 0.6
Age 37.4 ± 12.9 33.7 ± 8.6 40.8 ± 14.4 1.74 2 0.2
Cholesterol Levels (mg/dl)
Gender
Female 183.5 ± 35.3 176.0 ± 32.1 186.3 ± 40.4
Male 180.4 ± 48.5 173.8 ± 31.8 141.8 ± 27.1
     p ns ns .02
ns, non-significant at 5%.
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Our own findings are in agreement with the latter.  Both female PD and female GAD patients
had mean total cholesterol levels approximately the same as their male counterparts (p > .05) (Table
2).  Similar results were found for the whole sample (PD + GAD + MD) when compared male with
female subjects (p >.05) (Table 1).  In the same vein, a comparison between patient groups PD
(F+M), GAD (F+M), and MD (F+M) showed no significant differences in cholesterol levels (F =
0.46;  df = 2;  p = .0.6).  The only significant difference emerged on cholesterol level of female MD
subjects when compared with their male counterparts (p = .02).  A full understanding of this finding
calls for further analyses of covariance controlling for age and body mass, among other co-factors.
Conclusion
Our findings did not replicate those found by Hayward et al. and by Bajwa et al.  that PD
subjects had a significantly higher serum cholesterol level than normal controls or patients with
MD, and are in agreement with those reported by Reifman and Windle who found no such difference
between  PD, major depression only, and major depression with anxiety.
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